# Council Directive 92/66/EEC of 14 July 1992 introducing Community measures for the control of Newcastle disease, Division 2: Confirmatory identification

Extent: E+W+S+N.I.

The national laboratory should undertake full differential diagnosis of any haemagglutinating agent. Confirmation of Newcastle-disease virus would again be by inhibition in haemagglutination inhibition tests with monospecific chicken antisera. Intracerebral pathogenicity index tests as described in Chapter 7 should be carried out on all positive isolates. Pathogenicity indices of greater than 0,7 indicate the presence of virus requiring the full implementation of control measures.
Recent developments in typing Newcastle-disease viruses, particularly monoclonal antibody techniques, has enabled grouping of the strains and isolates. In particular, some monoclonal antibodies are available which are specific for the vaccinal strains used on the territory of the Community and can be employed in simple haemagglutination inhibition tests.
Since live vaccine strains may often be isolated from sampled poultry the advantage of their rapid identification at the national laboratory referred to in Annex II is obvious. Such monoclonal antibodies should be obtained by the Community reference laboratory as referred to in Article 14 and supplied to the national laboratories to enable confirmation of the isolation of vaccinal viruses.
The national laboratories should submit all haemagglutinating agents to the Community reference laboratory.

---
Source: https://www.legislation.gov.uk/eudr/1992/66/annex/III/chapter/3/division/2 (the official version)
Page: https://openlegislation.uk/eu-directive-1992-66/annex-III/chapter-3/division-2
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.